Medpace (NASDAQ:MEDP) Raised to Hold at UBS Group

Key Points

• UBS upgraded Medpace to “Hold”, while the broader analyst consensus remains “Hold” with three Buy ratings and ten Holds and an average price target of $602.27.
• Medpace delivered a strong quarter, reporting $4.25 in EPS versus the $3.98 estimate and $707.33 million in revenue, up 17.2% year over year and above expectations.
• Shares opened at $624.18, near the consensus target, while CEO August Troendle sold 2,410 shares for approximately $1.49 million; insiders still own 20.5% of the company.

Medpace (NASDAQ:MEDP - Get Free Report) was upgraded by investment analysts at UBS Group to a "hold" rating in a research report issued on Wednesday, Zacks reports.

Other equities research analysts also recently issued reports about the stock. Robert W. Baird lifted their price target on shares of Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a research report on Friday, July 24th. BMO Capital Markets increased their price target on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research report on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a research note on Thursday, July 23rd. Weiss Ratings raised Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 12th. Finally, TD Cowen upped their target price on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, Medpace currently has a consensus rating of "Hold" and an average price target of $602.27.

Medpace Price Performance

MEDP opened at $624.18 on Wednesday. The business has a fifty day simple moving average of $600.14 and a 200 day simple moving average of $519.59. Medpace has a 1 year low of $373.00 and a 1 year high of $677.90. The company has a market capitalization of $17.42 billion, a PE ratio of 36.59, a price-to-earnings-growth ratio of 2.78 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. During the same quarter last year, the business earned $3.10 EPS. The company's quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts anticipate that Medpace will post 17.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, CEO August Troendle sold 2,410 shares of Medpace stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $620.07, for a total value of $1,494,368.70. Following the transaction, the chief executive officer owned 386,892 shares in the company, valued at $239,900,122.44. The trade was a 0.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 287,473 shares of company stock valued at $177,687,399 over the last quarter. Company insiders own 20.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Schulhoff & Co. Inc. increased its position in Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company's stock worth $1,237,000 after purchasing an additional 25 shares in the last quarter. Balefire LLC lifted its stake in Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company's stock valued at $217,000 after purchasing an additional 26 shares during the last quarter. Root Financial Partners LLC boosted its position in Medpace by 34.1% in the first quarter. Root Financial Partners LLC now owns 122 shares of the company's stock valued at $59,000 after buying an additional 31 shares in the last quarter. GAMMA Investing LLC boosted its position in Medpace by 2.8% in the second quarter. GAMMA Investing LLC now owns 1,158 shares of the company's stock valued at $613,000 after buying an additional 32 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its stake in shares of Medpace by 0.6% during the second quarter. Handelsbanken Fonder AB now owns 7,020 shares of the company's stock worth $3,718,000 after buying an additional 40 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: UBS upgraded Medpace to “Neutral” from “Sell” and raised its price target to $673 from $405. The sharp target increase suggests UBS believes the company’s earnings outlook and recent share-price momentum have improved, even though the firm does not yet recommend buying the stock. UBS upgrades Medpace and raises price target
• Positive Sentiment: Medpace reported 17.2% second-quarter revenue growth. Its latest results also showed earnings per share of $4.25, above the $3.98 consensus estimate, while revenue of $707.33 million exceeded expectations of $689.51 million. Full-year 2026 earnings guidance remains $17.25-$17.95 per share, supporting the bullish fundamental case. Medpace reports second-quarter revenue growth
• Positive Sentiment: MEDP rose while the broader market declined. The relative strength indicates investors continued to favor the contract research organization after its earnings beat and revenue growth. Medpace rises as the market dips
• Neutral Sentiment: Analysts maintain an overall “Hold” consensus, with three Buy ratings and nine Holds and an average price target of $595.20. This target is below recent trading levels, suggesting valuation has already captured much of the expected improvement. Medpace receives average Hold rating
• Negative Sentiment: CEO August Troendle sold a combined 2,564 shares for roughly $1.59 million. The sales represent less than 1% of his holdings, so they are a modest negative signal rather than a major change in insider conviction. Medpace insider share sale

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.